←
Novocure2,179 posts
Novocure avatar✓

Novocure ✓

@Novocure

We strive to extend survival in some of the most aggressive forms of cancer. Patient images reflect patient(s) health status when photographed.

◷ Joined June 2013▧ 1,224 Photos and videos
Novocure avatar
Novocure@Novocure·Nov 16

JAMA Network Open published results of the prespecified secondary analysis of data from the PANOVA-3 trial of Novocure’s TTFields therapy concomitant with gemcitabine and nab-pac in patients with unresectable, locally advanced pancreatic adenocarcinoma: investor.novocure.com/news-r…

Post attachment
Novocure avatar
Novocure@Novocure·Nov 9

Novocure has received a Not Approvable Letter from the U.S. FDA in response to its Premarket Approval (PMA) application for its treatment for adult patients with brain metastases from non-small cell lung cancer following stereotactic radiation. Read more: investor.novocure.com/news-r…

Post attachment
Novocure avatar
Novocure@Novocure·Oct 28

Novocure announced its clinical trial agreement with Verastem Oncology to evaluate TTFields therapy with chemotherapy and VS-7375, Verastem’s investigational oral, potent and selective KRAS G12D (ON/OFF) inhibitor, in locally advanced pancreatic cancer: investor.novocure.com/news-r…

Post attachment
Novocure avatar
Novocure@Novocure·Oct 1

Novocure announced today that its treatment for adult patients diagnosed with unresectable locally advanced pancreatic cancer was approved by Japan’s Ministry of Health, Labour and Welfare (MHLW) for concomitant use with gemcitabine and nab-paclitaxel: investor.novocure.com/news-r…

Post attachment
Novocure avatar
Novocure@Novocure·Jun 30

Novocure announced today that its treatment has received CE Mark for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nab-paclitaxel in accordance with guideline recommendations. investor.novocure.com/news-r…

Novocure avatar
Novocure@Novocure·Mar 2

Today Novocure announced that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for its treatment for non-small cell lung cancer through the country’s National Health Insurance coverage. Read more in our press release: novocure.com/novocure-announ…

Post attachment